trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['gastric', 't-dxd', 'destiny,gastric02', '1205mo']
 update destiny-gastric02 at 1205mo t-dxd in 79 western pts her2+ gc/gej in 2nd line corr 41.8%, mpfs 5.6 mo, mos 12.1 mo qol maintained, safety manageable clinical benefit #gastriccancer 
Physician-scientist, focussed on translational research in hepatobiliary cancer and precision medicine